CN Patent

CN101119996A — 化学化合物

Assigned to AstraZeneca AB · Expires 2008-02-06 · 18y expired

What this patent protects

本发明涉及新的式(I)化合物：以及涉及它们的药物组合物并涉及它们的使用方法。这些新化合物提供癌症治疗。

USPTO Abstract

本发明涉及新的式(I)化合物：以及涉及它们的药物组合物并涉及它们的使用方法。这些新化合物提供癌症治疗。

Drugs covered by this patent

larotrectinib-sulfate (LAROTRECTINIB SULFATE)

Patent Metadata

Patent number: CN101119996A
Jurisdiction: CN
Classification: —
Expires: 2008-02-06
Drug substance claim: No
Drug product claim: No
Assignee: AstraZeneca AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.